New Age Alpha Advisors LLC Makes New $5.35 Million Investment in Balchem Co. (NASDAQ:BCPC)

New Age Alpha Advisors LLC purchased a new stake in shares of Balchem Co. (NASDAQ:BCPC - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 32,790 shares of the basic materials company's stock, valued at approximately $5,345,000. New Age Alpha Advisors LLC owned about 0.10% of Balchem as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of BCPC. Charles Schwab Investment Management Inc. increased its stake in shares of Balchem by 2.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 361,970 shares of the basic materials company's stock worth $63,707,000 after acquiring an additional 7,562 shares during the period. Citigroup Inc. boosted its holdings in Balchem by 61.1% in the third quarter. Citigroup Inc. now owns 43,178 shares of the basic materials company's stock valued at $7,599,000 after purchasing an additional 16,378 shares during the last quarter. Bank of Montreal Can grew its position in Balchem by 1.6% during the 3rd quarter. Bank of Montreal Can now owns 28,488 shares of the basic materials company's stock worth $4,989,000 after purchasing an additional 456 shares during the period. FMR LLC raised its stake in shares of Balchem by 944.3% during the 3rd quarter. FMR LLC now owns 497,495 shares of the basic materials company's stock valued at $87,559,000 after buying an additional 449,854 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Balchem by 21.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,356 shares of the basic materials company's stock valued at $3,759,000 after buying an additional 3,772 shares during the period. 87.91% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Sidoti raised Balchem to a "hold" rating in a report on Tuesday, February 25th. StockNews.com cut shares of Balchem from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th. Finally, HC Wainwright reiterated a "buy" rating and issued a $190.00 target price on shares of Balchem in a research note on Monday, February 24th.

Balchem Price Performance

NASDAQ BCPC traded down $0.43 during trading hours on Wednesday, reaching $166.81. The company's stock had a trading volume of 27,973 shares, compared to its average volume of 122,780. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. Balchem Co. has a 1-year low of $137.69 and a 1-year high of $186.03. The company's 50-day moving average is $165.46 and its two-hundred day moving average is $169.23. The firm has a market capitalization of $5.43 billion, a price-to-earnings ratio of 42.44, a P/E/G ratio of 4.41 and a beta of 0.63.

Balchem (NASDAQ:BCPC - Get Free Report) last announced its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.11 by ($0.08). The business had revenue of $240.00 million for the quarter, compared to analysts' expectations of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%. On average, equities analysts predict that Balchem Co. will post 4.64 EPS for the current year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.